179 related articles for article (PubMed ID: 35300361)
1. Prediction of hERG inhibition of drug discovery compounds using biomimetic HPLC measurements.
Stergiopoulos C; Tsopelas F; Valko K
ADMET DMPK; 2021; 9(3):191-207. PubMed ID: 35300361
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
[TBL] [Abstract][Full Text] [Related]
4. Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors.
Yu Z; IJzerman AP; Heitman LH
Br J Pharmacol; 2015 Feb; 172(3):940-55. PubMed ID: 25296617
[TBL] [Abstract][Full Text] [Related]
5. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.
DI Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
J Cardiovasc Electrophysiol; 2014 Feb; 25(2):197-207. PubMed ID: 24118558
[TBL] [Abstract][Full Text] [Related]
6. TSSF-hERG: A machine-learning-based hERG potassium channel-specific scoring function for chemical cardiotoxicity prediction.
Meng J; Zhang L; Wang L; Li S; Xie D; Zhang Y; Liu H
Toxicology; 2021 Dec; 464():153018. PubMed ID: 34757159
[TBL] [Abstract][Full Text] [Related]
7. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
8. Modulation of HERG potassium channels by extracellular magnesium and quinidine.
Po SS; Wang DW; Yang IC; Johnson JP; Nie L; Bennett PB
J Cardiovasc Pharmacol; 1999 Feb; 33(2):181-5. PubMed ID: 10028924
[TBL] [Abstract][Full Text] [Related]
9. ADMET Evaluation in Drug Discovery. 16. Predicting hERG Blockers by Combining Multiple Pharmacophores and Machine Learning Approaches.
Wang S; Sun H; Liu H; Li D; Li Y; Hou T
Mol Pharm; 2016 Aug; 13(8):2855-66. PubMed ID: 27379394
[TBL] [Abstract][Full Text] [Related]
10. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk.
Wible BA; Hawryluk P; Ficker E; Kuryshev YA; Kirsch G; Brown AM
J Pharmacol Toxicol Methods; 2005; 52(1):136-45. PubMed ID: 15950494
[TBL] [Abstract][Full Text] [Related]
11. A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery.
Kawai Y; Tsukamoto S; Ito J; Akimoto K; Takahashi M
Chem Pharm Bull (Tokyo); 2011; 59(9):1110-6. PubMed ID: 21881254
[TBL] [Abstract][Full Text] [Related]
12. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
13. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
14. Microfluidic cell culture and its application in high-throughput drug screening: cardiotoxicity assay for hERG channels.
Su X; Young EW; Underkofler HA; Kamp TJ; January CT; Beebe DJ
J Biomol Screen; 2011 Jan; 16(1):101-11. PubMed ID: 21131594
[TBL] [Abstract][Full Text] [Related]
15. Experimentally Validated Pharmacoinformatics Approach to Predict hERG Inhibition Potential of New Chemical Entities.
Munawar S; Windley MJ; Tse EG; Todd MH; Hill AP; Vandenberg JI; Jabeen I
Front Pharmacol; 2018; 9():1035. PubMed ID: 30333745
[TBL] [Abstract][Full Text] [Related]
16. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
[TBL] [Abstract][Full Text] [Related]
17. Compilation and physicochemical classification analysis of a diverse hERG inhibition database.
Didziapetris R; Lanevskij K
J Comput Aided Mol Des; 2016 Dec; 30(12):1175-1188. PubMed ID: 27783199
[TBL] [Abstract][Full Text] [Related]
18. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
Kongsamut S; Kang J; Chen XL; Roehr J; Rampe D
Eur J Pharmacol; 2002 Aug; 450(1):37-41. PubMed ID: 12176106
[TBL] [Abstract][Full Text] [Related]
20. Biomimetic membrane platform containing hERG potassium channel and its application to drug screening.
Arslan Yildiz A; Kang C; Sinner EK
Analyst; 2013 Apr; 138(7):2007-12. PubMed ID: 23423263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
